Tradestie Institutional Equity Comparison Engine
ENTX vs MBIO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ENTX Overall Edge
ENTX Captures Institutional Edge (2โ0 Pillars ยท 5โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Entera Bio Ltd. Ordinary Shares (ENTX) driven by superior Momentum & Technical, Options & Structure. Fundamentally, ENTX trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus MBIO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ENTX sits in CONSOLIDATION (32nd %ile IV; Dealer Gamma Walls on Pro) against MBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ENTX N/M vs MBIO N/M Fwd P/E
Growth & Margin Winner
Tie
Op Margin 0.0% vs 0.0% ยท YoY -100.0% vs +0.0%
Momentum & Technical Winner
ENTX
1Y +10.2% vs -68.4% ยท 52W Pos 64% vs 3%
Options & Structure Winner
ENTX
CONSOLIDATION (32nd %ile IV) vs UNCLASSIFIED (N/A IV)
ENTX
NASDAQ
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.02
-2.89% 1D
Market Cap
$541.6M
1M Return
+12.69%
1Y Return
+10.22%
Forward P/E
N/M
Unified AI Score
53.5 / 100
HOLD
Tech 35.0
Fund 55.0
Flow 72.0
Mom 60.0
MBIO
NASDAQ
Mustang Bio, Inc.
Pharmaceutical Preparations
$0.39
-2.46% 1D
Market Cap
$3.2M
1M Return
+3.22%
1Y Return
-68.44%
Forward P/E
N/M
Unified AI Score
42.9 / 100
HOLD
Tech 40.0
Fund 49.0
Flow 50.0
Mom 70.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ENTX +10.22%
MBIO -68.44%
Spread: +79.09 pp (ENTX Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ENTX TTM Op. Margin: 0.0%
MBIO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ENTX vs MBIO. Trailing 12-month operating profitability (ENTX 0.0% vs MBIO 0.0%) and valuation multiples (ENTX N/M vs MBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ENTX | MBIO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $541.6M | $3.2M | Larger Scale | ENTX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -100.0% | +0.0% | Higher Growth | MBIO |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -20.3% | -43.1% | Higher ROE | ENTX |
| 52-Week Range Position Momentum | 64% ($1โ$4) | 3% ($0โ$1) | Stronger Trend | ENTX |
| Beta / 30D Volatility Risk Regime | 1.07ฮฒ ยท 46% Vol | 0.68ฮฒ ยท 87% Vol | Lower Realized Risk | ENTX |
| Unified Institutional Score Composite Signal | 53.5 / 100 (HOLD) | 42.9 / 100 (HOLD) | Higher Composite | ENTX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ENTX vs MBIO Buy Guide
ENTX
CONSOLIDATION
79d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
32nd %ile
IV Regime
Balanced (25thโ60th %ile)
MBIO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ENTX nor MBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.